Nonalcoholic fatty liver disease (NAFLD) is the commonest chronic liver disease and affects a considerable proportion of the general population. NAFLD is independently associated with increased risk for cardiovascular events, particularly coronary heart disease. Importantly, even though NAFLD is more prevalent in patients with major cardiovascular risk factors (e.g. , type 2 diabetes mellitus, obesity and hypertension), the association between NAFLD and cardiovascular disease appears to be independent of these risk factors. However, NAFLD also appears to increase the risk for ischemic stroke, a leading cause of mortality and long-term disability worldwide. It also appears that nonalcoholic steatohepatitis is more strongly related to the risk of ischemic stroke than isolated hepatic steatosis. Moreover, emerging data suggest that patients with NAFLD experience more severe ischemic stroke and have more unfavorable prognosis after an acute ischemic stroke in terms of functional dependency and short-and long-term mortality. These associations have major public health implications, since ischemic stroke is the second leading cause of death worldwide and an important cause of long-term disability. The aim of the present review is to summarize the current knowledge regarding the relationship between NAFLD and ischemic stroke incidence, severity and outcome. Given these associations, it might be useful to evaluate patients with acute ischemic stroke for the presence of NAFLD and to manage those with NAFLD more aggressively. World J Hepatol 2018 July 27; 10(7): 474-478 ISSN 1948-5182 (online) fatty liver disease (NAFLD) is independently associated with increased risk for ischemic stroke, a leading cause of mortality and long-term disability worldwide. Moreover, emerging evidence shows that patients with NAFLD experience more severe ischemic stroke and have more unfavorable prognosis after an acute ischemic stroke in terms of functional dependency and shortand long-term mortality.
INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is the most frequent chronic liver disease, affects approximately 25% of the general population and is the leading cau se of abnormal liver function tests [1, 2] . Moreover, the prevalence of NAFLD is even higher in elderly subjects and in patients with type 2 diabetes mellitus (T2DM), obesity, hypertension and/or metabolic syndrome [2, 3] . Nonalcoholic steatohepatitis (NASH), a more advanc ed form of NAFLD, is present in up to 10% of adults [4] . NAFLD can progress to cirrhosis, hepatocellular cancer or liver failure, and is a major cause of liver transplant ation [3, 5] . Several studies showed that NAFLD is a risk factor for cardiovascular disease (CVD) [6, 7] . Importantly, ev en though NAFLD is more prevalent in patients with major cardiovascular risk factors (e.g., T2DM, obesity and hypertension), the association between NAFLD and CVD appears to be independent of these risk factors ( Figure 1 ) [6, 7] . In this context, accumulating data suggest that NAFLD is also associated with increased incidence of ischemic stroke. Moreover, emerging evidence sugge sts that NAFLD might also be related with more severe stroke and with worse outcome of patients with acute ischemic stroke. These associations have major public health implications, since ischemic stroke is the second leading cause of death worldwide and an important cause of longterm disability [8, 9] . The aim of the pre sent review is to summarize the current knowledge re garding the relationship between NAFLD and ischemic stroke incidence, severity and outcome.
NAFLD AND INCIDENCE OF ISCHEMIC

STROKE
Several studies reported that elevated aminotra nsferase and gglutamyltransferase (gGT) levels, which are mostly due to NAFLD, are associated with increased incidence of ischemic stroke (Table 1) . In a small casecontrol study in 103 patients with acute ischemic stroke and 200 controls, alanine or aspart ate aminotransferase levels were independently asso ciated with increased odds ratio for ischemic stroke [10] . In a larger prospective study in 6997 men without es tablished CVD or T2DM, gGT levels, a more specific marker of NAFLD, was independently associated with higher risk of ischemic stroke, even in subjects at low or moderate cardiovascular risk [11] . In EUROSTROKE, a nestedcase control study performed in 3 European countries (Finland, Netherlands and United Kingdom), the association between gGT levels and ischemic str oke risk appeared to be stronger in patients without T2DM [12] . Importantly, gGT appears to play a role in atherogenesis [13] . Indeed, gGT has been isolated fr om atheromatic plaques, macrophages and foam ce lls [14] and appears to contribute to atherosclerosis by inducing oxidative stress [15] . It was shown than gGT pr omotes oxidization of lowdensity lipoprotein and that it plays a crucial role in the catabolism of glutathione and the release of reactive oxygen species [16, 17] . In a recent crosssectional study, NAFLD diagnosed with ultrasonography was associated with increased pr evalence of lacunar infarcts in nonobese subjects but not in obese patients [18] . In contrast, in another recent casecohort study in 572 patients with incident is chemic stroke and 1017 controls, NAFLD defined as fatty liver index > 60 was associated with lower risk in men but there was no association in women [19] . In a metaanalysis of 9 casecontrol and cohort studies, NAFLD was independently associated with 2.3 times higher risk for ischemic stroke (95%CI: 1.842.93) [20] . The strength of this association was comparable in Caucasian and Asian patients [20] . Importantly, this as sociation was independent of traditional cardiovasc ular risk factors, including dyslipidemia, obesity and T2DM [20] . It appears that NASH is more strongly related to the risk of ischemic stroke than isolated hepatic ste atosis. Indeed, in a casecontrol study in 295 pat ients with acute ischemic stroke and 1942 subjects who underwent a health checkup, the degree of liver fibrosis, evaluated with transient elastography, was independently associated with increased stroke risk [21] . In contrast, isolated steatosis was not related with the risk of stroke [21] .
NAFLD AND SEVERITY AND OUTCOME
OF ISCHEMIC STROKE
There are very few data regarding the impact of NA FLD on the severity and outcome of ischemic stroke (Table 1) . In an early prospective study in 200 patients admitted with acute ischemic stroke, NAFLD (defined as elevated aminotransferase levels in the absence of oth er causes) was present in 42.5% of patients [22] . Patien had more severe stroke at admission and higher risk for neurological deterioration during hospitalization, independently of other risk factors [23] . In contrast, in a prospective study in 415 consecutive patients with acute ischemic stroke, stroke severity at admission, functional outcome at discharge and inhospital mortality did not differ between patients with NAFLD (defined as elevat ed aminotransferase levels without another apparent cause) and those without NAFLD after adjustment for other cardiovascular risk factors [24] . However, only 32 patients (7.7% of the study population) had NAFLD [24] . Therefore, this study might have lacked the power to ts with NAFLD had more severe stroke at admission and worse functional outcome at discharge [22] . Howev er, patients with NAFLD were more obese, had higher prevalence of T2DM and had higher lowdensity lipoprotein cholesterol and triglyceride levels than pa tients without NAFLD; these differences were not adjusted for in the comparisons of stroke severity and outcome between the 2 groups [22] . In a more recent retrospective study in 306 patients with brainstem in farction, a similar prevalence of NAFLD (defined as el evated aminotransferase levels in the absence of other causes) was reported (42.5%) [23] . Patients with NAFLD [7] Prospective observational study in 1637 healthy Japanese men/women 47.8 2 yr Higher incidence of CVD including stroke in patients with NAFLD compared with controls [22] Prospective study in 242 patients admitted with acute stroke 66 2 yr Increased risk of acute stroke, more severe stroke and worse outcome in patients with NAFLD [11] Prospective study in 6997 men with no history of CVD or diabetes mellitus 40-59 24 yr Association between gGT and higher incidence of fatal, major stroke events and total CVD mortality [10] Cross sectional study in adults with suspected acute stroke 20-27 Not applicable Elevated ALP and ALT levels independently associated with higher risk of acute stroke [12] Case-control study using data from 3 European cohort studies in 13177 subjects 40-60 3-8 yr Elevated gGT levels associated with higher risk of stroke [21] Case-control study in 295 patients with acute stroke and 1942 healthy subjects 60 Not applicable Liver fibrosis was associated with higher incidence of ischemic stroke [20] Meta analysis of 9 studies that examined relation of NAFLD and stroke Not reported Not applicable Higher risk of ischemic stroke and hemorrhagic stroke in patients with NAFLD [23] Retrospective study in 306 patients with confirmed brainstem infractions Figure 1 Mechanisms underpinning the association between nonalcoholic fatty liver disease and ischemic stroke (broken line suggests the independent association between nonalcoholic fatty liver disease and ischemic stroke).
identify an association between NAFLD and stroke se verity and outcome [24] .
CONCLUSION
Accumulating data suggest that NAFLD is independ ently associated with increased risk for ischemic st roke. Moreover, it appears that patients with NAFLD experience more severe stroke and have more adve rse functional outcome than patients without NAFLD. Therefore, it might be useful to evaluate patients with acute ischemic stroke for the presence of NAFLD and to manage those with NAFLD more aggressively. It re mains to be established whether management of NA FLD will also reduce the risk and improve the outcome of ischemic stroke.
